Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | BAZ2A | Q9UIF9 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13164975 | 0.89 | PTGER4 (0.49) | PTGER4PRKACARPS6KB1GSK3BROCK1 | |
| SCHEMBL3496135 | 0.87 | OGFRL1 (0.47) | PTGER4BRD4KDM4EHSD17B10BAZ2A | |
| SCHEMBL3496085 | 0.79 | PRKACA (0.48) | PTGER4PRKACARPS6KB1GSK3BROCK1 | |
| SCHEMBL13164978 | 0.77 | BRD4 (0.45) | PTGER4BRD4KDM4EBAZ2AALDH1A1 | |
| SCHEMBL3497158 | 0.76 | PRKACA (0.46) | PTGER4PRKACARPS6KB1GSK3BROCK1 | |
| SCHEMBL3495473 | 0.71 | PTPN1 (0.48) | ALDH1A1 | |
| SCHEMBL2866244 | 0.69 | HDAC1 (0.71) | ALDH1A1 | |
| SCHEMBL287420 | 0.69 | ALDH1A1 (0.74) | ALDH1A1 | |
| SCHEMBL15774961 | 0.69 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL22029484 | 0.68 | BRD4 (0.51) | PTGER4PRKACARPS6KB1GSK3BROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | PTGER4 677/4885PRKACA 2930/4885RPS6KB1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.